

REMARKS

In view of the newly submitted Sequence Listing and the comments which follow, amendment and reconsideration of the Official Action of July 2, 2003 is respectfully requested by Applicants.

In the Office Communication mailed July 2, 2003, the Examiner commented that the application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the enclosed Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. The Examiner commented that the amino acid sequences set forth in the specification as filed, for example, page 6, includes L amino acids, not just D amino acids.


Applicants point out that the sequences previously submitted in their Sequence Listing were those sequences disclosed in their application comprising L amino acids; the sequences comprising D amino acids were not included in the listing in accordance with 37 CFR 1.821(a)(2). A substitute Sequence Listing, however, has been prepared using a newer version of PatentIn software than that used previously. If the listing is still incorrect, the Examiner is invited to please telephone the undersigned to explain what exactly is not in compliance.

Applicants submit that their application is now in condition for allowance, and favorable reconsideration of their application in light of the current amendments and remarks is respectfully requested.

* * * * *

The Examiner is hereby authorized to charge any fees associated with this Amendment to Deposit Account No. 50-0877. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

A handwritten signature in cursive script, reading "Marilyn L. Amick", written over a horizontal line.

Marilyn L. Amick

Reg. No. 30,444

Roche Diagnostics Corp.
9115 Hague Road
Indianapolis, IN 46250
Phone: 317-521-7561
Fax: 317-521-2883